Kennedy Capital Management LLC Boosts Stake in Edwards Lifesciences Co. (NYSE:EW)

Kennedy Capital Management LLC increased its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 25.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 192,518 shares of the medical research company's stock after purchasing an additional 39,472 shares during the quarter. Kennedy Capital Management LLC's holdings in Edwards Lifesciences were worth $14,252,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of EW. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences in the fourth quarter valued at $26,000. Millstone Evans Group LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $30,000. Roble Belko & Company Inc acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $46,000. Finally, Catalyst Capital Advisors LLC bought a new stake in Edwards Lifesciences in the fourth quarter worth approximately $54,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Shares of EW stock traded up $1.06 on Friday, reaching $69.32. The company's stock had a trading volume of 4,890,092 shares, compared to its average volume of 4,914,207. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25. The stock's 50 day simple moving average is $71.32 and its 200-day simple moving average is $70.70. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $40.75 billion, a P/E ratio of 9.95, a PEG ratio of 4.82 and a beta of 1.15.

Remove Ads

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares of the company's stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the company's stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total transaction of $797,287.50. Following the completion of the sale, the chief financial officer now directly owns 30,387 shares in the company, valued at $2,153,526.69. This represents a 27.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 62,853 shares of company stock worth $4,534,247 in the last ninety days. 1.29% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have commented on EW. Truist Financial reduced their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday. Wolfe Research lowered shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Bank of America upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and lifted their price target for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their target price for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, Morgan Stanley increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $78.55.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.